Sofinnova Partners

Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs and occasionally restarts. Our focus is on life sciences. We proactively source deals, take a lead role, we are most often the first institutional investor in Round A financings, and we lead our portfolio companies until exit. We sit on the boards of our portfolio companies and play an active role as from the formation phase alongside our entrepreneurs. Sofinnova invests throughout Europe from our headquarters in Paris with a portion of our investments made in the rest of the world.

Type
Investor
HQ
Paris, FR
Founded
1972
Sofinnova Partners was founded in 1972 and is headquartered in Paris, FR

Key People at Sofinnova Partners

Rafaèle Tordjman

Rafaèle Tordjman

Managing Partner
Denis Lucquin

Denis Lucquin

Managing Partner
Graziano Seghezzi

Graziano Seghezzi

Managing Partner
Antoine Papiernik

Antoine Papiernik

Chairman
Monique Saulnier

Monique Saulnier

Managing Partner & CFO
Henrijette Richter

Henrijette Richter

Partner
Joško Bobanović

Joško Bobanović

Partner
Jean-Jacques Garaud

Jean-Jacques Garaud

Venture Partner
Gérard Hascoët

Gérard Hascoët

Venture Partner
Anne Horgan

Anne Horgan

Senior Associate
Michael Krel

Michael Krel

Senior Associate
Adam Evertts

Adam Evertts

Associate
Sara Nunez Garcia

Sara Nunez Garcia

Principal

Sofinnova Partners Office Locations

Sofinnova Partners has an office in Paris

Sofinnova Partners Investment Portfolio

Stage Distribution

Top Sectors Distribution

Round Size Distribution

Sofinnova Partners News and Updates

Grapeless Wine And Cowless Milk: 60+ Synthetic Biology Startups In A Market Map

Over the past five years, funding to synthetic biology startups has more than tripled, surpassing the $1B mark for the first time in 2016. Deal flow has also grown significantly, up over 150% since 2012. We define synthetic biology as … Continued

Amsterdam-based myTomorrows raises €10 million to improve access to drugs in development

Amsterdam-based myTomorrows, a platform to help patients and doctors access drugs in development, has closed a €10 million growth funding round. The round was led by EQT Ventures and Octopus Ventures, with participation from existing investors Balderton Capital and Sofinnova Partners. The post Amste…

MyTomorrows raises $10.5 million to connect doctors and patients with early-stage drug programs

MyTomorrows, an online platform that connects physicians and patents to early-stage drug research and development programs, has raised €10 million ($10.5 million) in a funding round co-led by Octopus Ventures and EQT Ventures, with participation from existing investors Balderton Capital and Sofinnov…

MyTomorrows raises further €10M to help access drugs in development

 MyTomorrows, the Netherlands-headquartered startup that has built a platform to help physicians and patients access drugs that are still in development, has raised €10 million in further funding. Leading the round is EQT Ventures, and Octopus Ventures, with participation from existing backers Balde…

Term Sheet — Thursday, December 8

On deals and dealmakers.

Term Sheet — Wednesday, November 23

On deals and dealmakers.
Show more

Traffic Overview of Sofinnova Partners

Sofinnova Partners Company Life and Culture